Patents by Inventor Cyril Y. Bowers
Cyril Y. Bowers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9724381Abstract: The invention provides methods for treatment, prevention or management of obesity, obesity related disorders, diabetes mellitus, and metabolic syndrome in a subject by administering a ghrelin O-acyltransferase (GOAT) inhibitor and/or a ghrelin receptor antagonist to the subject. The invention also provides ghrelin receptor antagonists of formula (VII): A11-A12-A13-Gly-Ser-A14-Phe-Leu-A15-A16-A17-A18, wherein each of A11, A12, and A13 is independently absent, an amino acid, or an amino protecting group; each of A15, A16, A17, and A18 is independently absent or an amino acid; and A14 is a serine conjugated with a —C(O)C1-C20alky or a diaminopropionic acid conjugated with a —C(O)C1-C20alkyl group, provided that at least one of A11, A12, or A13 is present.Type: GrantFiled: October 2, 2014Date of Patent: August 8, 2017Assignees: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, MCGILL UNIVERSITYInventors: Cyril Y. Bowers, David H. Coy, Gloria S. Tannenbaum
-
Publication number: 20170049849Abstract: The invention provides methods for treatment, prevention or management of obesity, obesity related disorders, diabetes mellitus, and metabolic syndrome in a subject by administering a ghrelin O-acyltransferase (GOAT) inhibitor and/or a ghrelin receptor antagonist to the subject. The invention also provides ghrelin receptor antagonists of formula (VII): A11-A12-A13-Gly-Ser-A14-Phe-Leu-A15-A16-A17-A18, wherein each of A11, A12, and A13 is independently absent, an amino acid, or an amino protecting group; each of A15, A16, A17, and A18 is independently absent or an amino acid; and A14 is a serine conjugated with a —C(O)C1-C20alky or a diaminopropionic acid conjugated with a —C(O)C1-C20alkyl group, provided that at least one of A11, A12, or A13 is present.Type: ApplicationFiled: October 2, 2014Publication date: February 23, 2017Applicants: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, MCGILL UNIVERSITYInventors: Cyril Y. BOWERS, David H. COY, Simon J. HOCART, Gloria S. TANNENBAUM
-
Patent number: 9315546Abstract: The present invention provides novel peptides that can modulate the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and sub-types, isoforms and variants thereof). These peptides are useful as antagonists of the ghrelin receptor as well as inverse agonist, partial agonist or a combination of these activities as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, diabetes, central nervous system disorders, genetic disorders, and hyperpro-liferative disorders.Type: GrantFiled: June 16, 2011Date of Patent: April 19, 2016Assignees: The Administrators of the Tulane Educational Fund, McGill UniversityInventors: Cyril Y. Bowers, David H. Coy, Simon J. Hocart, Gloria S. Tannenbaum
-
Publication number: 20150031605Abstract: The invention provides methods for treatment, prevention or management of obesity, obesity related disorders, diabetes mellitus, and metabolic syndrome in a subject by administering a ghrelin O-acyltransferase (GOAT) inhibitor and/or a ghrelin receptor antagonist to the subject. The invention also provides ghrelin receptor antagonists of formula (VII): A11-A12-A13-Gly-Ser-A14-Phe-Leu-A15-A16-A17-A18, wherein each of A11, A12, and A13 is independently absent, an amino acid, or an amino protecting group; each of A15, A16, A17, and A18 is independently absent or an amino acid; and A14 is a serine conjugated with a —C(O)C1-C20alky or a diaminopropionic acid conjugated with a —C(O)C1-C20alkyl group, provided that at least one of A11, A12, or A13 is present.Type: ApplicationFiled: October 2, 2014Publication date: January 29, 2015Inventors: Cyril Y. BOWERS, David H. COY, Simon J. HOCART, Gloria S. TANNENBAUM
-
Patent number: 8883721Abstract: The invention provides methods for treatment, prevention or management of obesity, obesity related disorders, diabetes mellitus, and metabolic syndrome in a subject by administering a ghrelin O-acyltransferase (GOAT) inhibitor and/or a ghrelin receptor antagonist to the subject. The invention also provides ghrelin receptor antagonists of formula (VII): A11-A12-A13-Gly-Ser-A14-Phe-Leu-A15-A16-A17-A18 (SEQ ID NO: 93), wherein each of A11, A12, and A13 is independently absent, an amino acid, or an amino protecting group; each of A15, A16, A17, and A18 is independently absent or an amino acid; and A14 is a serine conjugated with a —(O)C1-C20alky or a diaminopropionic acid conjugated with a —C(O)C1-C20alkyl group, provided that at least one of A11, A12, or A13 is present.Type: GrantFiled: May 12, 2010Date of Patent: November 11, 2014Assignees: McGill University, The Administrators of the Tulane Educational FundInventors: Cyril Y. Bowers, David H. Coy, Simon J. Hocart, Gloria S. Tannenbaum
-
Patent number: 8536120Abstract: The present invention provides novel compounds that have been demonstrated to be modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, iso forms and variants thereof). These compounds are useful as antagonists of the ghrelin receptor as well as inverse agonist, partial agonist or a combination of these activities as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, diabetes, central nervous system disorders, genetic disorders, and hyperproliferative disorders.Type: GrantFiled: April 30, 2007Date of Patent: September 17, 2013Assignee: The Administrators of The Tulane Educational FundInventors: Cyril Y. Bowers, Gloria S. Tannenbaum, David H. Coy, Simon J. Hocart
-
Publication number: 20130172242Abstract: The present invention provides novel peptides that can modulate the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and sub-types, isoforms and variants thereof). These peptides are useful as antagonists of the ghrelin receptor as well as inverse agonist, partial agonist or a combination of these activities as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, diabetes, central nervous system disorders, genetic disorders, and hyperproliferative disorders.Type: ApplicationFiled: June 16, 2011Publication date: July 4, 2013Applicants: MCGILL UNIVERSITY, THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUNDInventors: Cyril Y. Bowers, David H. Coy, Simon J. Hocart, Gloria S. Tannenbaum
-
Publication number: 20120135918Abstract: The invention provides methods for treatment, prevention or management of obesity, obesity related disorders, diabetes mellitus, and metabolic syndrome in a subject by administering a ghrelin O-acyltransferase (GOAT) inhibitor and/or a ghrelin receptor antagonist to the subject. The invention also provides ghrelin receptor antagonists of formula (VII): A11-A12-A13-Gly-Ser-A14-Phe-Leu-A15-A16-A17-A18, wherein each of A11, A12, and A13 is independently absent, an amino acid, or an amino protecting group; each of A15-A16-A17, and A18 is independently absent or an amino acid; and A14 is a serine conjugated with a —C(O)C1-C20alky or a di-aminopropionic acid conjugated with a —C(O)C1-C20alkyl group, provided that at least one of A11, A12, or A13 is present.Type: ApplicationFiled: May 12, 2010Publication date: May 31, 2012Applicants: MCGILL UNIVERSITY, THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUNDInventors: Cyril Y. Bowers, David H. Coy, Simon J. Hocart, Gloria S. Tannenbaum
-
Publication number: 20090069245Abstract: The present invention provides novel compounds that have been demonstrated to be modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, iso forms and variants thereof). These compounds are useful as antagonists of the ghrelin receptor as well as inverse agonist, partial agonist or a combination of these activities as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, diabetes, central nervous system disorders, genetic disorders, and hyperproliferative disorders.Type: ApplicationFiled: April 30, 2007Publication date: March 12, 2009Applicant: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUNDInventors: Cyril Y. Bowers, Gloria S. Tannenbaum, David H. Coy, Simon J. Hocart
-
Patent number: 7250399Abstract: Compounds that promote growth hormone releasing activity are disclosed. These compounds have the formula: A1-A2-X; A1?-X?; or A1?-Y These compounds can be present in a pharmaceutical composition. The compounds can be used with a second compound that acts as an agonist at the growth hormone releasing hormone receptor or which inhibits the effects of somatostatin. These compounds can be used for a variety of uses such as treating hypothalamic pituitary dwarfism, osteoporosis, burns, or promoting wound healing.Type: GrantFiled: March 29, 2002Date of Patent: July 31, 2007Assignee: The Administrators of the Tulane Educational FundInventors: Cyril Y. Bowers, Frank Momany, Yongwu Liang
-
Patent number: 6468974Abstract: Compounds that promote growth hormone releasing activity are disclosed. These compounds have the formula: A1-A2-X; Al1′-X′; or A1″-Y These compounds can be present in a pharmaceutical composition. The compounds can be used with a second compound that acts as an agonist at the growth hormone releasing hormone receptor or which inhibits the effects of somatostatin. These compounds can be used for a variety of uses such as treating hypothalamic pituitary dwarfism, osteoporosis, burns, or promoting wound healing.Type: GrantFiled: August 6, 1999Date of Patent: October 22, 2002Assignee: The Administrators of the Tulane Educational FundInventors: Cyril Y. Bowers, Frank Momany, Yongwu Liang
-
Publication number: 20020151501Abstract: Compounds that promote growth hormone releasing activity are disclosed.Type: ApplicationFiled: March 29, 2002Publication date: October 17, 2002Inventors: Cyril Y. Bowers, Frank Momany, Yongwu Liang
-
Patent number: 5776901Abstract: Novel peptides of the formula A.sub.1 -A.sub.2 -C.sub.1 -C.sub.2 -C.sub.3 -A.sub.5 are disclosed which promote the release of growth hormone when administered to animals. These peptides can be used therapeutically.Type: GrantFiled: August 20, 1992Date of Patent: July 7, 1998Assignee: Administrators of the Tulane Educational FundInventors: Cyril Y. Bowers, David Coy
-
Patent number: 5763404Abstract: Antide is the decapeptide, N-Ac-D-2-Nal,D-pClPhe, D-3-Pal, Ser,NicLys, D-NicLys, Leu, ILys, Pro, D-Ala,NH.sub.2 which is an antagonist of luteinizing hormone releasing hormone (LHRH). This decapeptide, like others of the present invention, has high antiovulatory activity (AOA) and releases negligible histamine. Antide is scheduled for scale-up, safety testing and evaluation in the experimental primate and in clinical medicine. Numerous other peptides having structures related to Antide were prepared and tested. These peptides had variations primarily in positions 5, 6, 7, and 8. Of these, N-Ac-D-2-Nal, D-pClPhe,D-3-Pal,Ser,PicLys,cis-DPzACAla,Leu,ILys,Pro,D-Ala-NH.sub.2 was one of the most potent and had higher antiovulatory activity than Antide, i.e. 73%/0.25 ug and 100%/0.5 ug vs. 36%/0.5 ug and 100%/1.0 ug. Antide showed significant, (p<0.001) duration of action, when injected at a dose of 10 ug, 44 hours before 50 ng of the agonist, ?D-3-Qal.sup.6 !-LHRH.Type: GrantFiled: June 6, 1995Date of Patent: June 9, 1998Inventors: Karl A. Folkers, Cyril Y. Bowers, Anders Ljungqvist, Pui-Fun Louisa Tang, Minoru Kubota, Dong-Mei Feng
-
Patent number: 5663146Abstract: Novel peptides of the formula A.sub.1 -A.sub.2 -Ala-Trp-DPhe-A.sub.5 are disclosed which promote the release of growth hormone when administered to animals. These peptides can be used therapeutically.Type: GrantFiled: August 22, 1991Date of Patent: September 2, 1997Assignee: Administrators of the Tulane Educational FundInventors: Cyril Y. Bowers, David Coy
-
Patent number: 5656727Abstract: LHRH analogs and congeners with high water solubility have been synthesized. These new analogs had 0%-100% antiovulatory activity at a 0.5 .mu.g dosage and 0%-80% at 0.25 .mu.g. The ED.sub.50 for histamine release was 30.5 .mu.g/ml->300 .mu.g/ml.Type: GrantFiled: April 28, 1995Date of Patent: August 12, 1997Assignees: The Administrators of the Tulane Educational Fund, Board of Regents, The University of Texas SystemInventors: Cyril Y. Bowers, Karl A. Folkers, Anna Janecka
-
Patent number: 5534494Abstract: Disclosed are novel polypeptide compounds which promote the release and elevation of growth hormone levels in the blood of animals. Also disclosed are methods of promoting the release and elevation of growth hormone levels in the blood of animals using the disclosed polypeptide compounds.Type: GrantFiled: April 21, 1994Date of Patent: July 9, 1996Assignee: Polygen Holding CorporationInventors: Cyril Y. Bowers, Frank A. Momany, Ching H. Chang, Wayne L. Cody, John C. Hubbs, Charles H. Foster
-
Patent number: 5486505Abstract: Novel polypeptides which promote the release of growth hormone when administered to animals are described. These polypeptides have the formula:A.sub.1 --D.sup..beta. Nal--A.sub.3 --Trp--A.sub.5 --A.sub.6 --Zwherein A.sub.1, A.sub.3, A.sub.5, A.sub.6 and Z" are as defined in the specification.Type: GrantFiled: October 16, 1992Date of Patent: January 23, 1996Assignee: Polygen Holding CorporationInventors: Cyril Y. Bowers, Wayne L. Cody, John C. Hubbs, Charles H. Foster, Frank A. Momany
-
Patent number: 5480969Abstract: LHRH antagonists similar to antide and congeners with higher water solubility have been synthesized by substitutions in positions 1, 5 or 6 with hydrophilic residues. These peptides have antiovulatory activity with minimal histamine releasing effect.Type: GrantFiled: September 15, 1992Date of Patent: January 2, 1996Assignees: The Administrators of the Tulane Educational Fund, Board of Regents, The University of Texas SystemInventors: Cyril Y. Bowers, Karl A. Folkers, Anders Ljungqvist, Dong-Mei Feng, Anna Janceka
-
Patent number: 5470947Abstract: Antide is the decapeptide, N--Ac--D--2--Nal,D--pClPhe, D--3--Pal, Ser,NicLys, D--NicLys, Leu, ILys, Pro, D--Ala,NH.sub.2 which is an antagonist of luteinizing hormone releasing hormone (LHRH). This decapeptide, like others of the present invention, has high antiovulatory activity (AOA) and releases negligible histamine. Antide is scheduled for scale-up, safety testing and evaluation in the experimental primate and in clinical medicine. Numerous other peptides having structures related to Antide were prepared and tested. These peptides had variations primarily in positions 5, 6, 7, and 8. Of these, N--Ac--D--2--Nal, D--pClPhe,D--3--Pal,Ser,PicLys,cis--DpzACAla, Leu,ILys,pro,D--Ala--NH.sub.2 was one of the most potent and had higher antiovulatory activity than Antide, i.e. 73%/0.25 ug and 100%/0.5 ug vs. 36%/0.5 ug and 100%/1.0 ug. Antide showed significant, (p<0.001) duration of action, when injected at a dose of 10 ug, 44 hours before 50 ng of the agonist, [D--3--Qal.sup.6 ]--LHRH.Type: GrantFiled: June 26, 1989Date of Patent: November 28, 1995Assignees: Board of Regents, The University of Texas System, The Administrators of the Tulane Educational FundInventors: Karl A. Folkers, Anders Ljungqvist, Dong-Mei Feng, Minoru Kubota, Pui-Fun L. Tang, Cyril Y. Bowers